US IPO Pipeline SEC S-1 Filings — October 05, 2026

05-10-2026

New Iceland Arctic Acquisition Corp. filed an S-1 registration statement with the SEC on October 2, 2026, for an initial public offering of 10,000,000 units at $10.00 per unit, with total gross proceeds of $100,000,000 ($115,000,000 if the over-allotment option is exercised in full). The SPAC will deposit the proceeds into a trust account and must complete an initial business combination within 12 months of the offering closing. However, the filing highlights significant risks: the Sponsor acquired founder shares at a nominal price, creating a conflict of interest where management could profit even if the business combination subsequently declines in value for public shareholders, and the net tangible book value per share after the offering is negative under certain redemption scenarios (e.g., -$0.38 per share assuming no over-allotment and maximum redemption).

• · The company is an 'emerging growth company' and a 'smaller reporting company' under federal securities laws, subject to reduced public company reporting requirements.
• · The underwriter is offering the public units on a firm commitment basis.
• · The trust account is established by Continental Stock Transfer & Trust Company as trustee.
• · The company is incorporated in the Cayman Islands and no offer is being made to the public in the Cayman Islands.
• · The founder shares (Class B ordinary shares) were purchased by the Sponsor at a nominal price, leading to immediate and substantial dilution for public shareholders upon closing.
• · The Sponsor and initial shareholders have a conflict of interest: they could profit even if the business combination causes the trading price of ordinary shares to decline materially.
• · If no business combination is completed within the 12-month completion window, the founder shares and private units may become worthless.
• · The company's securities are expected to trade on Nasdaq under symbols 'NIAA', 'NIAAW', and 'NIAAR' for Class A ordinary shares, public warrants, and public rights, respectively.
• · The underwriter has committed to use $0.20 per unit from the underwriting discount to purchase private placement units.
• · Deferred underwriting commissions of $0.30 per public unit ($3,000,000 aggregate) will be placed in the trust account and released only upon completion of an initial business combination.

05-10-2026

Quantum Space, LLC is merging with SPAC Inflection Point Acquisition Corp. VI via a business combination, with the combined entity to be named Quantum Space, Inc. The S-4 registration statement, filed October 2, 2026, details the transaction, including the issuance of up to 106,680,270 shares of Class A-1 common stock, 6,272,380 shares of Series A preferred stock, and warrants. The deal is subject to shareholder approval and regulatory effectiveness, with no financial performance data disclosed in this filing.

• · The Business Combination Agreement was approved by Inflection Point's board on June 7, 2026, and signed on June 8, 2026.
• · The transaction includes a domestication of Inflection Point from the Cayman Islands to Delaware, followed by a merger with Merger Sub.
• · Quantum Space will undergo a recapitalization, converting most equity into common units, with exceptions for Series B convertible preferred units and warrants issued to Pre-Funded PIPE Investors.
• · The combined company will operate under an Up-C structure, with Quantum Space OpCo as a subsidiary.
• · The registration statement is not yet effective, and securities may not be issued until SEC approval.

05-10-2026

Equity Bancshares Inc. filed an S-4 registration statement with the SEC on October 2, 2026, in connection with its merger with Lincoln Bancorp, a private company. The filing includes Lincoln's unaudited financial statements for the six months ended June 30, 2026, which show a net loss of $13.19 million (compared to a net loss of $1.207 million in the prior period), driven by a $15.69 million realized loss on the sale of available-for-sale debt securities. While net interest income improved 4.2% to $22.684 million, total noninterest income swung to a loss of $9.297 million from a gain of $5.920 million, and total assets declined 2.2% to $1.722 billion.

• · Lincoln Bancorp is a private company and does not file reports with the SEC.
• · The merger consideration consists of shares of Equity common stock.
• · Lincoln's net interest margin improved as interest expense declined 17.6% (H1 2026 vs H1 2025) while interest income fell only 7.4%.
• · Noninterest expense increased 10.6% to $30.824 million in H1 2026 from $27.866 million in H1 2025.
• · Total stockholders' equity remained nearly flat at $137.590 million (Jun 30, 2026) vs $137.814 million (Dec 31, 2025).
• · The company's accumulated other comprehensive loss improved to -$10.301 million from -$22.492 million due to gains on AFS securities and cash flow hedges.

05-10-2026

Tigerless Health, Inc. filed Form S-4 for a business combination with SPAC PVAC. The filing details a post-merger dual-class stock structure where Zikang Wu will hold all Class B common stock and 100% voting control, while public Class A common stock will have no voting rights. The filing warns that the trading price of PVAC Ordinary Shares post-combination may be substantially below the Trust Account per-share value, and that there is no maximum redemption threshold, allowing the deal to proceed even if a substantial majority of shareholders redeem.

• · No maximum redemption threshold exists, allowing the business combination to close even if a substantial majority of shareholders redeem.
• · Shareholders acting as a group holding more than 15% of Public Shares lose redemption rights for shares exceeding that threshold.
• · Redemption deadline is 5:00 p.m. ET on [•], 2026 (two business days before the Shareholder Meeting).
• · Obtaining physical stock certificates may take significantly longer than two weeks, potentially preventing shareholders from meeting the redemption deadline.
• · Pubco will be a 'controlled company' under Nasdaq rules and may opt out of independent director and committee requirements.
• · The filing warns that shares of most recent SPAC-business-combination companies have traded substantially below $10.00 per share.
• · Litigation risk is highlighted, including potential securities class actions related to the business combination.

05-10-2026

Lycia Therapeutics, Inc. filed an S-1 registration statement with the SEC on October 5, 2026, for its initial public offering of common stock. The clinical-stage biotechnology company, which focuses on degrading extracellular proteins to treat autoimmune, inflammatory, and allergic diseases, plans to list on the Nasdaq Global Market under the symbol 'LYCA'. The offering is in the early stages, with the price range and number of shares left blank, and highlights include Phase 1 data for lead candidate LCA-0061 showing rapid IgE reduction, though the company is still pre-revenue and faces significant risks typical of early-stage biotech IPOs.

• · LCA-0061 is a cataLYTAC degrader designed to target and degrade IgE; preliminary data from a single 70 mg SC dose showed rapid, deep, and sustained reduction in total and free IgE in healthy atopic participants.
• · LCA-0062 is in IND-enabling activities; LCA-0321 (Graves' disease program) is in Phase 1; initial data for both programs are expected but dates are redacted.
• · Xolair's food allergy launch in 2024 outpaced Dupixent and Skyrizi launches in atopic dermatitis and plaque psoriasis, respectively.
• · The company is an emerging growth company and smaller reporting entity and has elected to comply with reduced reporting requirements.
• · The offering is contingent upon Nasdaq listing approval; no public market currently exists for Lycia's common stock.

05-10-2026

Propanc Biopharma, Inc. (PPCB) filed an S-1 registration statement on October 5, 2026, covering the fiscal year ended June 30, 2026. The filing details a series of financing transactions, including a securities purchase agreement with 1800 Diagonal Lending LLC and multiple promissory notes, with related-party involvement. The company also entered into a debt exchange agreement with a former director and a loan agreement with CrownBridge Partners LLC, indicating ongoing reliance on dilutive and debt financing.

• · Securities purchase agreement with 1800 Diagonal Lending LLC dated July 22, 2025, with multiple drawdown dates through January 2026.
• · Debt exchange agreement with a former director executed on January 23, 2025.
• · Loan agreement with CrownBridge Partners LLC dated August 19, 2025, with related-party involvement.
• · Promissory note with 1800 Diagonal Lending LLC dated June 13, 2025, with maturity extension agreements.
• · Multiple promissory note drawdowns under the securities purchase agreement with 1800 Diagonal Lending LLC during fiscal 2026.

05-10-2026

Evolution Metals & Technologies Corp. (formerly Welsbach Technology Metals Acquisition Corp.) filed an S-1 registration statement on October 5, 2026, for a proposed IPO. The filing includes financial statements for the six months ended June 30, 2026, and the year ended December 31, 2025, with restatement adjustments for prior periods. The company reports significant debt from convertible debentures and related-party transactions, and its operations are concentrated in South Korea with exposure to various Korean financial institutions.

• · The filing includes restatement adjustments for the six months ended June 30, 2025, and the year ended December 31, 2025.
• · Convertible debentures are a significant component of the company's financing, with multiple tranches issued.
• · The company has relationships with several Korean financial institutions for guarantees and loans.
• · Related-party transactions are disclosed, including shareholder loan advances and transactions with EMT Asia.
• · The company has noncontrolling interests and equity-classified CPU share allocation obligations.